Stocks · News reference
Wave Life Sciences shares are trading lower after JP Morgan downgraded the stock from Overweight to Neutral rating. The company also announced the initiation of its Phase 2a clinical trial evaluating WVE-007 in combination with tirzepatide in adults living with obesity.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
This Dow Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Analysts downgraded SoundThinking, Moderna, Accelerant, Mobileye and Dow, revising their ratings and price targets.
Wave Life Sciences Announces $12M Milestone As GSK Selects Liver Disease Candidate For Development
This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Analysts downgraded Ryder, Warner Bros. Discovery, Arbor Realty, Pershing Square and PepsiCo; Ryder and PepsiCo targets were cut.